Glutathione
RecoveryPreclinicalAlso known as: GSH
Glutathione is the body's most abundant intracellular antioxidant — a three-amino-acid peptide made of glutamate, cysteine, and glycine (Glu-Cys-Gly), present in millimolar concentrations inside every cell of your body. It is not a research peptide in the same sense as BPC-157 or Semax; it is a fundamental metabolic molecule that your liver synthesizes constantly from its amino acid components.
Overview
At A Glance
Glutathione's mechanisms extend far beyond the simple "antioxidant" label that dominates popular marketing. Understanding these mechanisms matters because they determine where supplementation is likely to help and where it is unlikely to make any difference.…
Mechanism of Action
Glutathione's mechanisms extend far beyond the simple "antioxidant" label that dominates popular marketing. Understanding these mechanisms matters because they determine where supplementation is likely to help and where it is unlikely to make any difference.
Direct free radical scavenging. The reduced form GSH contains a free thiol (-SH) group on its cysteine residue, which can directly donate an electron to neutralize reactive oxygen species (ROS) — particularly hydroxyl radicals, peroxynitrite, and singlet oxygen. When GSH gives up its electron, two GSH molecules become oxidized together into GSSG (glutathione disulfide). This is a fast, one-step reaction that does not require enzymes, though it is also a minor fraction of GSH's total antioxidant activity compared to its enzymatic cofactor roles. The reaction is: 2 GSH + ROS → GSSG + reduced ROS + H2O.
Glutathione peroxidase cofactor. Glutathione's most quantitatively important antioxidant role is as the substrate for glutathione peroxidase (GPx) enzymes, which detoxify hydrogen peroxide (H2O2) and organic hydroperoxides (lipid peroxides, DNA hydroperoxides). The reaction is: 2 GSH + H2O2 → GSSG + 2 H2O. This is the primary enzymatic defense against lipid peroxidation, which is a central driver of membrane damage in aging, neurodegeneration, and chronic inflammation. GPx isoforms exist in cytosol (GPx1), membranes (GPx4 — particularly important for ferroptosis prevention), and specific tissues.
Glutathione-S-transferase and Phase II detoxification. GSH is the substrate for the glutathione-S-transferase (GST) enzyme family, which conjugates GSH onto electrophilic toxins, xenobiotics, and metabolites — making them water-soluble and eliminable in bile or urine. This is the core of Phase II liver detoxification. Compounds detoxified via GSH conjugation include: acetaminophen reactive metabolite (NAPQI), many chemotherapy agents, heavy metals (mercury, arsenic), environmental toxins (PAHs, aldehydes), alcohol metabolism byproducts (acetaldehyde), and endogenous electrophiles (4-HNE, MDA from lipid peroxidation). This mechanism is why acute GSH depletion (acetaminophen overdose, certain chemotherapy regimens) is so dangerous — without GSH, electrophilic metabolites accumulate and cause cell death.
Glutathione reductase and the redox cycle. Oxidized glutathione (GSSG) is continuously regenerated back to GSH by glutathione reductase, using NADPH as the electron donor. NADPH itself is regenerated by the pentose phosphate pathway, which is why metabolic flux through the PPP (driven by glucose-6-phosphate dehydrogenase) is so critical to maintaining redox balance. Individuals with G6PD deficiency have impaired NADPH regeneration and therefore impaired GSH recycling — this is the biochemistry behind oxidative hemolytic crises triggered by certain drugs and foods in G6PD-deficient individuals.
Protein glutathionylation (S-glutathionylation). Beyond passive antioxidant roles, GSH can be covalently attached to protein cysteine residues via disulfide bonds, modifying protein function. This post-translational modification is reversible (removed by glutaredoxins) and regulates the activity of numerous enzymes and signaling proteins. Targets include: transcription factors (NF-kB, AP-1), metabolic enzymes (glyceraldehyde-3-phosphate dehydrogenase, protein tyrosine phosphatases), cytoskeletal proteins (actin), and apoptosis regulators (caspases). Glutathionylation is increasingly recognized as a regulatory mechanism comparable to phosphorylation in complexity.
Mitochondrial GSH and electron transport protection. Mitochondria have their own GSH pool, imported via specific transporters from the cytosol. Mitochondrial GSH is critical for protecting the inner mitochondrial membrane from oxidative damage generated by electron transport chain leak. Complex I and Complex III are major sites of electron leak and ROS generation; mitochondrial GSH protects these complexes and downstream membrane lipids from oxidative damage. Mitochondrial GSH depletion is implicated in aging, neurodegeneration, heart failure, and NAFLD — and mitochondrial GSH is harder to replete than cytosolic GSH, which is part of why some conditions respond to GSH-precursor supplementation and others do not (Marí et al., 2009).
Melanin synthesis regulation (skin effects). Glutathione inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis, and shifts melanocyte output from eumelanin (dark pigment) toward pheomelanin (light pigment). This is the biochemistry behind glutathione's skin-lightening effects — well-documented in clinical use in Asian dermatology and cosmetic practice, with meaningful effect sizes at IV doses but more modest effects with oral or topical use (Sonthalia et al., 2016).
Immune system support. Lymphocytes require adequate GSH for proliferation, cytokine production, and antigen response. GSH depletion impairs T-cell and B-cell function. In HIV infection, GSH depletion in lymphocytes correlates with disease progression, and GSH-replenishing interventions (NAC, liposomal GSH) have been studied for immune support. In general chronic inflammatory states, GSH supports appropriate immune cell function without producing immunosuppression.
Blood-brain barrier and CNS considerations. Intact GSH does not cross the blood-brain barrier efficiently, which is why IV glutathione rarely increases brain GSH levels meaningfully. Intranasal delivery bypasses the BBB via olfactory and trigeminal pathways, which is why intranasal glutathione has been specifically studied for Parkinson's disease and other CNS conditions. Brain GSH can also be raised indirectly by providing cysteine precursors (NAC, whey protein) that cross the BBB and are used for local GSH synthesis within neurons and glia (Mischley et al., 2013).
Ferroptosis prevention. Glutathione peroxidase 4 (GPx4), which uses GSH as substrate, is the primary enzyme that prevents ferroptosis — a form of iron-dependent programmed cell death driven by lipid peroxidation. Ferroptosis is increasingly recognized in neurodegeneration, ischemia-reperfusion injury, and certain cancers. Adequate GSH is essential for GPx4 function and ferroptosis suppression. This is a relatively recent but important addition to the glutathione mechanism story.
What glutathione does NOT do. Despite marketing claims, glutathione does not directly "flush" toxins in any vague or magical sense — its detoxification role is specific, via Phase II conjugation. It does not "reset" the immune system in any broad sense. It does not directly stimulate muscle growth, testosterone, growth hormone, or any anabolic pathway. It does not "burn fat" or suppress appetite. It is not a general panacea — it is a specific biochemical cofactor with specific, well-characterized roles.
Pharmacokinetic caveats. Oral glutathione bioavailability has historically been estimated as very low (< 5%) due to gastrointestinal peptidase degradation. More recent work with specific formulations (liposomal, S-acetyl-glutathione) suggests somewhat higher bioavailability, though absolute numbers are debated. IV glutathione bypasses GI degradation but the plasma half-life is short (on the order of minutes to tens of minutes), and cellular uptake of intact GSH is limited — most of the cellular GSH pool comes from local synthesis using cysteine, glutamate, and glycine as substrates rather than from intact GSH uptake. This is why NAC (providing rate-limiting cysteine) is sometimes more effective at raising cellular GSH than direct GSH administration.
Interactions with other antioxidants. Glutathione works synergistically with vitamin C (which recycles vitamin E radicals back to active form, with GSH in turn helping regenerate vitamin C), alpha-lipoic acid (can regenerate GSH and recycle other antioxidants), selenium (cofactor for GPx enzymes), and Methylene Blue (affects different redox systems but may complement GSH in mitochondrial protection). This is the biochemical basis for "antioxidant network" supplementation protocols.
Overview
Glutathione is the body's most abundant intracellular antioxidant — a three-amino-acid peptide made of glutamate, cysteine, and glycine (Glu-Cys-Gly), present in millimolar concentrations inside every cell of your body. It is not a research peptide in the same sense as BPC-157 or Semax; it is a fundamental metabolic molecule that your liver synthesizes constantly from its amino acid components. The interest in supplemental glutathione stems from the observation that tissue GSH levels decline with age, with chronic disease, with oxidative stress, and with certain medications — and that restoring GSH levels may improve outcomes in conditions ranging from fatty liver disease to Parkinson's disease to chemotherapy-induced toxicity.
Chemically, glutathione exists in two interconvertible forms: the reduced form (GSH), which is the antioxidant-active form with a free thiol (-SH) group, and the oxidized form (GSSG), in which two GSH molecules are linked by a disulfide bond. The ratio of GSH to GSSG in a cell is one of the most reliable biochemical markers of oxidative stress — a healthy cell maintains a GSH:GSSG ratio of roughly 100:1, while cells under oxidative stress see this ratio collapse. The dynamic regeneration of GSH from GSSG by the enzyme glutathione reductase (using NADPH as the reducing equivalent) is one of the core redox cycles of cellular metabolism (Lu, 2013).
Glutathione has a broad range of biological functions that go beyond simple antioxidant activity. It directly scavenges reactive oxygen species. It is a cofactor for glutathione peroxidases, the enzymes that detoxify hydrogen peroxide and lipid peroxides. It is the substrate for glutathione-S-transferases, which conjugate toxins and xenobiotics to glutathione for elimination — this is the core of Phase II liver detoxification for everything from acetaminophen to heavy metals to alcohol metabolism byproducts. It regulates cell signaling through protein glutathionylation. It supports mitochondrial function, particularly in complex I and complex III of the electron transport chain. It is essential for lymphocyte function and immune system activity. It is the key reducing agent for vitamin C recycling and for the proper function of vitamin E (Forman et al., 2009).
The practical problem with supplementing glutathione is bioavailability. Oral glutathione is largely broken down by gastrointestinal peptidases before it can be absorbed intact, and even the fraction that enters systemic circulation has difficulty crossing cell membranes to reach intracellular compartments where it is needed. This is the central question that has driven the development of alternative formulations: intravenous glutathione (bypasses GI degradation but still has cellular uptake limits), liposomal glutathione (protects the molecule in the gut and may improve uptake), intranasal glutathione (bypasses first-pass metabolism, delivers directly to brain via olfactory/trigeminal routes), nebulized glutathione (delivers to lung tissue), and glutathione precursors like N-acetylcysteine (NAC), which provides the rate-limiting cysteine for endogenous synthesis (Sechi et al., 1996, Schmitt et al., 2015).
Clinical evidence for glutathione supplementation is strongest in a few specific contexts. Acetaminophen overdose is the textbook case — N-acetylcysteine administration to replenish hepatic GSH is standard of care and saves lives, with an evidence base spanning decades. Nonalcoholic fatty liver disease (NAFLD) has seen multiple small trials of oral and IV glutathione showing improvements in ALT, oxidative stress markers, and liver histology. Parkinson's disease has a growing body of research on intranasal and IV glutathione, based on observations that Parkinson's patients have reduced GSH in the substantia nigra and that GSH supplementation may have neuroprotective and symptomatic effects. Cystic fibrosis has trials of inhaled glutathione for lung function improvement. Chemotherapy-induced neuropathy and ototoxicity has trials suggesting IV glutathione may reduce certain chemotherapy side effects (Testa et al., 2016, Honda et al., 2017).
The research peptide and longevity community uses glutathione much more broadly than these evidence-supported indications. Common use patterns include: general anti-aging and longevity support, skin brightening and melanin reduction (popular in Asian markets), hangover prevention and recovery, support during heavy training or physical stress, liver support during alcohol use or medication courses, "detox" protocols (a vague concept but biochemically coherent for glutathione's role in Phase II conjugation), and as a supportive agent in fatigue syndromes, chronic Lyme disease, and environmental illness. Evidence for these uses ranges from suggestive to entirely anecdotal.
The mythology around IV glutathione "detox" has outpaced the evidence. True detoxification — removal of specific toxins through Phase II conjugation — is a well-characterized biochemical process that glutathione is central to. But the popular concept of "flushing toxins" through IV glutathione drips is largely marketing built on the real biochemistry. Similarly, the skin-brightening use of IV glutathione is documented and real — glutathione inhibits tyrosinase and shifts melanin synthesis from eumelanin (dark) toward pheomelanin (light) — but it comes with safety concerns the marketing rarely mentions, especially in the high-dose IV protocols marketed in beauty clinics, which the FDA has specifically warned against.
Glutathione is not FDA-approved as a drug in the United States except in specific formulations (e.g., for prevention of platinum chemotherapy neuropathy in some jurisdictions; nebulized forms for cystic fibrosis trials). It is available as an over-the-counter supplement in oral, liposomal, and sublingual forms. IV and nebulized formulations are typically prepared by compounding pharmacies and administered in clinical settings. Intranasal formulations are increasingly available as compounded prescriptions or from reputable peptide suppliers.
If you are considering glutathione supplementation, the honest framing is this: glutathione is a real biochemical entity with real physiological roles, and there are specific contexts (acetaminophen overdose, NAFLD, early Parkinson's, cystic fibrosis) where supplementation has coherent evidence of benefit. Beyond those contexts, use is largely empirical — driven by mechanism and by subjective reports of benefit rather than by strong trials. It is generally safe at typical supplement doses, it stacks cleanly with most other health practices, and at worst it is an expensive placebo. At best, in appropriate contexts, it is one of the more scientifically grounded interventions in the longevity and biohacking space.
Chemical Information
IUPAC Name
(2S)-2-amino-4-{[(1R)-1-[(carboxymethyl)carbamoyl]-2-sulfanylethyl]carbamoyl}butanoic acid
CAS Number
70-18-8
Molecular Formula
C10H17N3O6S
Molecular Mass
307.32 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Glutathione has an exceptionally favorable safety profile, but specific contraindications and cautions apply, particularly for IV and high-dose protocols and for specific patient populations.
Absolute contraindications (do not use):
Known hypersensitivity to glutathione or formulation excipients. Prior anaphylactoid or severe allergic reaction to GSH or components of a specific formulation (liposomes, preservatives, sulfite-containing preparations) is an absolute contraindication to repeat use of that formulation. Alternative formulations may or may not be tolerated — decide case-by-case with clinical input.
Active chemotherapy with specific agents WITHOUT oncology coordination. Some chemotherapy mechanisms depend on generating reactive species or forming electrophilic intermediates that GSH can conjugate and inactivate. Platinum-based drugs (cisplatin, carboplatin, oxaliplatin), alkylating agents (cyclophosphamide), and certain targeted therapies have theoretical interaction with GSH. The interaction is complex: GSH may reduce specific toxicities (neuropathy, ototoxicity, nephrotoxicity) while potentially also reducing antitumor efficacy. This requires oncologist-level decision-making, NOT community self-dosing.
Active asthma or reactive airway disease with high-dose nebulized GSH. Nebulized GSH can precipitate bronchospasm. If using nebulized GSH in asthmatic patients, pre-medicate with bronchodilator and do so under clinical oversight. Patients with severe or unstable asthma should avoid nebulized glutathione.
Relative contraindications (caution, specific considerations):
Pregnancy and lactation. No established evidence of harm, but rigorous safety data are absent. Low-dose oral GSH (250-500 mg daily) is probably acceptable but IV and high-dose protocols should be avoided without specific medical indication. Consult obstetrician.
Severe asthma, COPD, or reactive airway disease. Even non-nebulized high-dose GSH formulations may carry some airway risk in sensitive individuals. Start with oral forms; avoid nebulized unless clinically indicated and supervised.
Recent solid organ transplant. GSH supports immune function; its effect on transplant immunosuppression is theoretical. Discuss with transplant medicine team before use.
Severe hepatic dysfunction. GSH is typically therapeutic rather than contraindicated in liver disease, but in advanced cirrhosis or acute liver failure, specific medical oversight is appropriate. Self-treatment of serious liver disease with supplements is not a substitute for specialist care.
Severe renal dysfunction. Minor pharmacokinetic changes; no specific contraindication but clinical oversight appropriate.
Active infection. No specific contraindication. GSH is generally supportive of immune function rather than immunosuppressive. However, in sepsis or serious infection, focus should be on appropriate antimicrobial therapy, not on supplement decisions.
Specific drug interaction concerns:
Chemotherapy agents (cisplatin, carboplatin, oxaliplatin, alkylating agents). Interaction requiring oncology coordination — see above.
Nitrates (nitroglycerin, isosorbide). GSH is involved in nitrate bioactivation. Chronic high-dose GSH theoretically could affect nitrate tolerance or efficacy. Practical relevance uncertain; discuss with cardiologist if on chronic nitrate therapy.
Acetaminophen in overdose. GSH/NAC are therapeutic, not contraindicated — but timing is critical in overdose management, which requires emergency department care.
Immunosuppressants (tacrolimus, cyclosporine, mycophenolate). No clinically significant direct interaction. However, GSH's immune-supportive role may theoretically oppose immunosuppression. Transplant or autoimmune patients should discuss with prescribing physician.
Anticoagulants (warfarin, DOACs). No clinically significant interaction.
Antiplatelet agents (aspirin, clopidogrel). No clinically significant interaction.
Statins. No interaction; may be modestly protective against statin side effects.
Thyroid hormone replacement. No interaction; separate GSH from thyroid hormone by 2-3 hours for optimal thyroid absorption.
Diabetes medications (metformin, insulin, GLP-1 agonists). No direct interaction. GSH may support metabolic health modestly. Monitor glucose as with any supplement change in diabetic patients.
Specific formulation considerations.
IV glutathione: Requires clinical administration. Monitor for hypersensitivity on first administration. Anaphylactoid reactions, while rare, can be serious.
Nebulized glutathione: Bronchospasm risk. Pre-medicate with bronchodilator. Clinical supervision for initial doses.
Intranasal glutathione: Rare local irritation. Generally well-tolerated.
Topical glutathione: Occasional contact sensitization. Test on small skin area before widespread use.
Genetic considerations.
G6PD deficiency. GSH is generally safe; in fact, may be protective against the oxidative stress that causes hemolytic crisis in G6PD-deficient individuals. However, avoid concurrent use of oxidant drugs (certain antimalarials, dapsone, fava beans) that can precipitate hemolysis.
CBS mutations. Cystathionine beta-synthase mutations affect sulfur metabolism. High-dose GSH and NAC protocols may produce unpredictable effects. Consider lower doses and genetic counseling.
MTHFR polymorphisms. Generally compatible with standard GSH dosing. May affect methylation status in ways that interact with GSH stack components. Comprehensive genetic/methylation evaluation may be appropriate for advanced protocols.
Glutathione S-transferase (GST) polymorphisms. Common variants affect individual detoxification capacity. Those with reduced GST function may benefit more from GSH support; those with enhanced GST may have different optimal doses. Genetic testing is available but not routinely needed for supplementation decisions.
Age considerations.
Pediatrics: Used in specific contexts (cystic fibrosis research, autism spectrum trials) with pediatric specialist guidance. Not recommended for general pediatric use without medical supervision.
Geriatrics: GSH depletion increases with age, making supplementation theoretically more relevant in older adults. The GlyNAC study specifically showed benefits in older adults. Standard or slightly lower doses are appropriate; monitor for drug interactions which are more common in polypharmacy settings.
Stop GSH and seek medical evaluation for:
- Allergic reaction signs (hives, wheezing, facial swelling)
- Persistent bronchospasm with nebulized forms
- Unexplained liver enzyme elevations
- New onset renal dysfunction
- Unexpected infection or unusual severity of minor infections
- Any progressive or severe symptom correlating with GSH use
Not contraindications (common misconceptions):
- History of sulfa antibiotic allergy (different sulfur chemistry from GSH)
- Active flu or cold (GSH may actually be supportive)
- Concurrent vitamin or mineral supplementation (compatible)
- Moderate alcohol consumption (GSH may help with liver support)
- Active exercise training (though timing considerations apply for adaptation)
- Diabetes (compatible, may be modestly supportive)
- Hypertension (no interaction)
- Most prescription medications (few clinically significant interactions)
Pre-use baseline evaluation.
For advanced or high-dose protocols:
- CBC with differential
- Comprehensive metabolic panel
- Liver function (ALT, AST, GGT, bilirubin, albumin)
- Kidney function (creatinine, eGFR, urinalysis)
- Oxidative stress markers if accessible
- Current medications and supplements review
- Specific condition markers as indicated
- Genetic screening (G6PD, CBS, MTHFR) for unusual presentations or high-dose protocols
When in doubt, defer to physician input. GSH is a specific biochemical compound with specific effects — it is not a "natural substance" in the sense of being risk-free or beyond consideration. Most patients can use standard oral doses without concern, but advanced protocols warrant oversight.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$15.00
up to $55.00
$0.0137
4
8
powder, vial, strip, liquid
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
Glutathione Raw 1g | powder | 1g● Out of Stock | $15.00BEST | $0.015 | — | Sign in for stock alert |
|
|
Glutathione 600mg | vial | 1 vial● In Stock | $29.00 | $0.048 | — | |
|
|
Glutathione Buccal Strip | strip | 1 strip pack● In Stock | $35.00 | — | — | |
|
|
Glutathione 750mg | vial | 1 vial● Out of Stock | $35.00 | $0.047 | — | Sign in for stock alert |
|
|
Glutathione 1500mg | vial | 1 vial● In Stock | $55.00 | $0.037 | — | |
 |
Glutathione 600mg Vial | vial | 1 vial● In Stock | $54.00 | $0.090 | ||
 |
Glutathione 200mg/mL 20mL | liquid | 20mL● In Stock | $54.99 | $0.014 | ||
 |
Glutathione 200mg | vial | 200mg vial● In Stock | $29.99 | $0.150 |
Tracking since Apr 3, 2026 · 7 data points
Price History
3 data pointsVendors Selling Glutathione
Ion Peptide
VANDL Labs
Nova Peptides
Limitless Biochem EU
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Side-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for Glutathione
Related Articles
All PostsIon Peptide Review 2026: BPC-157, GLP-1s, Buccal Strips & Bioregulators
A complete look at Ion Peptide (ionpeptide.com) — 92 products spanning research peptides, GLP-1 agonists, NAD+/B12/glutathione buccal strips, copper peptide topicals, Khavinson bioregulators, and PDRN. We cover pricing, testing, shipping, unique offerings, and how they compare to other vendors on BodyHackGuide.
4/21/2026Adera State Review: Is the 5 States System Worth It? [Honest Assessment]
An honest, in-depth review of Adera State's 5 States nootropic system — product-by-product ingredient analysis, what we liked, what we didn't, and who should (and shouldn't) buy it.
4/3/2026The Biohacker's Complete Nootropic Stack Guide
10 research-backed nootropic stacks for every goal: focus, memory, anxiety, sleep, motivation, creativity, and more. Complete dosing protocols, timing, cycling, and product recommendations.
4/1/2026Research Score
203023 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Well-researched compound
Quick Facts
Molecular Weight
307.32 g/mol
CAS Number
70-18-8
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Does oral glutathione actually work, or is it all destroyed in digestion?
The answer depends on formulation and what you mean by 'work.' Standard oral glutathione (GSH capsules) has historically been assumed to have very low bioavailability (<5%) due to gastrointestinal peptidase degradation. More recent formulations — liposomal glutathione, S-acetyl-glutathione, sublingual — show meaningfully higher bioavailability, with some studies suggesting liposomal GSH can increase blood and tissue GSH levels measurably. A 2015 study of 500 mg liposomal GSH over 1-2 weeks showed increased red blood cell GSH, reduced oxidative stress markers, and improved immune parameters (Sinha et al., 2018). However, the best-studied approach for increasing cellular GSH is often NOT direct GSH supplementation but rather providing the rate-limiting precursor cysteine (via N-acetylcysteine, NAC). For most users, a combination of moderate-dose liposomal GSH plus NAC probably provides better cellular GSH than either alone. Standard (non-liposomal) GSH at typical doses is probably not useless but is likely less efficient than the alternatives.
Is IV glutathione worth the cost compared to oral forms?
For most users seeking general anti-aging or wellness benefits, probably not. IV glutathione at clinical doses (600-1500 mg per session, $80-250 per session) achieves 100% systemic bioavailability and produces higher peak plasma levels than oral — but the GSH clears quickly (plasma half-life of minutes to tens of minutes) and cellular uptake of intact GSH is limited. Most tissues rely on local GSH synthesis, not plasma GSH uptake. For specific medical indications (acute NAFLD, Parkinson's disease, chemotherapy adjunct therapy, diagnosed oxidative stress conditions), IV may be worth the investment under clinical supervision — the higher peak levels may matter in these contexts. For general wellness, longevity, or routine antioxidant support, a well-designed oral protocol (liposomal GSH + NAC + glycine + selenium + vitamin C) is more cost-effective and probably equally or more effective at raising tissue GSH. The marketing of IV glutathione for general 'detox' or 'anti-aging' in wellness clinics often outstrips the evidence. Save the IV protocols for specific medical indications with clinical oversight.
Can glutathione lighten my skin?
Yes, glutathione has documented skin-lightening effects, but the magnitude depends heavily on route and dose. IV glutathione produces the most pronounced effects; oral produces more modest results; topical produces local spot-lightening effects. The mechanism is inhibition of tyrosinase (rate-limiting enzyme in melanin synthesis) and shift from eumelanin (dark) to pheomelanin (light) production (Sonthalia et al., 2016). Typical IV protocols of 600-1200 mg twice weekly produce visible lightening over 4-12 weeks. The FDA has specifically warned about high-dose (multi-gram) IV skin-lightening protocols marketed at beauty clinics, citing reports of kidney and liver adverse events and severe skin reactions. At medical IV doses with clinical supervision, the safety profile is reasonable. At ultra-high cosmetic doses, the risk/benefit is concerning. Oral routes are safer but less effective — expect modest lightening over 3-6 months at 500-1000 mg daily liposomal. An important consideration: skin lightening from glutathione requires ongoing use; effects reverse over weeks to months after discontinuation.
What's the difference between glutathione and NAC?
NAC (N-acetylcysteine) is a precursor; glutathione is the end product. NAC provides cysteine, which is the rate-limiting amino acid for GSH synthesis. Your body makes GSH from cysteine + glutamate + glycine in a two-step enzymatic process. Supplementing GSH directly gives you exogenous GSH (with bioavailability challenges); supplementing NAC gives your body the building block to make more GSH locally in cells where it's needed. In many contexts, NAC is MORE effective than direct GSH supplementation at raising cellular GSH — because cellular synthesis delivers GSH exactly where it's needed, not just to the bloodstream. NAC is also far cheaper than liposomal GSH. The clinical evidence base for NAC is much larger than for oral GSH in most indications (acetaminophen overdose, chronic bronchitis, exercise recovery, various psychiatric indications). In most cases, if you had to pick one, NAC is the more evidence-supported and cost-effective choice. Combining NAC with GSH (or with precursor glycine as in the GlyNAC protocol) may be better than either alone for specific indications.
Can I take glutathione for a hangover?
Mechanistically, there's a plausible rationale — alcohol metabolism generates acetaldehyde and reactive oxygen species that deplete GSH, contributing to hangover symptoms. Replenishing GSH should theoretically help. In practice, the clinical evidence specifically for hangover prevention or treatment is limited. A few small trials have shown modest benefit of GSH-related interventions (NAC, liposomal GSH) taken before or during alcohol consumption. The typical approach that has anecdotal support: 500 mg liposomal GSH + 600-1200 mg NAC before drinking, and again before bed if drinking heavily. This provides cysteine for GSH replenishment during alcohol metabolism. Realistic expectations: this probably helps with mild hangover symptoms and liver support but will NOT prevent hangover from heavy drinking — the neurological and dehydration components of hangover are not GSH-mediated. Hydration, sleep, and simply drinking less remain the highest-yield interventions. GSH/NAC as hangover adjuncts are reasonable but not miraculous.
Does glutathione help with fatty liver disease?
There's moderate evidence for benefit. NAFLD is characterized by oxidative stress in hepatocytes, mitochondrial dysfunction, and inflammation — all areas where GSH function is relevant. A 2017 Japanese RCT of oral glutathione 300 mg daily for 4 months in NAFLD patients showed significant ALT reduction compared to placebo (Honda et al., 2017). Italian trials of IV glutathione have shown similar biomarker improvements. The evidence is stronger than for general 'wellness' indications but weaker than for established NAFLD interventions (weight loss, vitamin E, GLP-1 agonists, pioglitazone in NASH). A reasonable protocol for NAFLD: oral liposomal GSH 500 mg BID + NAC 600 mg BID + TUDCA 500 mg BID, combined with weight loss (dietary or GLP-1-assisted) and exercise. If liver enzymes do not improve over 3 months on this regimen, escalation to IV GSH with integrative medicine oversight may be worth considering. But the foundation of NAFLD treatment remains weight loss and metabolic improvement — GSH is an adjunct, not a substitute.
Can glutathione help with Parkinson's disease?
Emerging evidence suggests a possible role, but it is not established treatment. The mechanistic case is strong: Parkinson's disease involves depletion of GSH in the substantia nigra, and this GSH depletion appears early in disease progression — even before dopaminergic neuron loss. Intranasal GSH bypasses the blood-brain barrier and may deliver GSH to relevant brain regions. A pilot RCT of intranasal glutathione 200 mg daily over 3 months showed safety and suggested functional improvement in early PD (Mischley et al., 2015). Subsequent larger trials have shown mixed results — some functional improvement, unclear magnitude. IV glutathione for PD has been used for decades in some European neurology clinics with observational benefit reports. Bottom line: intranasal and IV GSH may be reasonable adjunctive therapies for PD under neurologist supervision, particularly in early or mild disease. They should NOT replace standard PD therapy (levodopa, MAO-B inhibitors, dopamine agonists). For most PD patients interested in GSH: intranasal 200 mg daily is a reasonable protocol to discuss with the treating neurologist.
How long until I notice glutathione working?
This depends on what you're expecting to notice. For subjective effects — energy, clarity, general well-being — glutathione typically does NOT produce acute noticeable effects. Most users notice 'nothing' for the first 2-4 weeks, which is normal. Where you might notice changes: skin appearance (4-12 weeks), recovery after exercise (2-4 weeks for subtle improvement), alcohol/toxic exposure tolerance (immediate but modest), post-meal bloating or 'heaviness' (variable, 1-4 weeks). For objective biomarker changes: liver enzymes (ALT, AST) may improve over 4-8 weeks on adequate protocols. Oxidative stress markers (8-OHdG, F2-isoprostanes) typically improve over 4-12 weeks. Intracellular GSH levels on lab testing: 2-8 weeks depending on formulation. If you're expecting a dramatic subjective 'lift' from GSH, recalibrate — this is a foundational metabolic support compound, not a stimulant or nootropic. If after 12 weeks of adequate dosing (500-1000 mg daily liposomal, plus NAC and other stack components) you see no benefit in any measurable way, GSH is probably not the right intervention for your situation.
Is glutathione safe during chemotherapy?
This is complex and requires oncology coordination. Glutathione's mechanisms can both help AND potentially hurt chemotherapy outcomes, depending on the specific regimen. Some chemotherapy drugs (cisplatin, oxaliplatin, alkylating agents) partly work by generating reactive species or forming electrophilic intermediates that GSH can conjugate and inactivate. In theory, high-dose GSH during active chemotherapy could reduce drug efficacy. In practice, the evidence is mixed — some studies show GSH reduces chemotherapy toxicity (neuropathy, nephrotoxicity, ototoxicity) without obvious loss of antitumor efficacy; others suggest caution. Some oncology protocols intentionally include IV GSH before or after specific chemo regimens for side effect reduction; others avoid it. The absolute requirement: do NOT take high-dose GSH (especially IV) during chemotherapy without explicit oncologist coordination. A typical approach for patients on chemotherapy seeking to use GSH: discuss with oncologist, possibly use low-dose oral forms (250-500 mg liposomal daily) between chemo cycles, avoid high-dose or IV protocols during active chemotherapy. Some integrative oncology programs have specific protocols that work alongside chemotherapy — that's the right setting.
What should I stack with glutathione for maximum effect?
The most evidence-supported stacks are precursor-based. The GlyNAC protocol (glycine + N-acetylcysteine) has clinical trial data showing improvements in mitochondrial function, oxidative stress, insulin resistance, and cognitive function in older adults (Kumar et al., 2021). For a comprehensive antioxidant network, combine: liposomal GSH 500 mg daily + NAC 600 mg BID + glycine 3-5 g daily + alpha-lipoic acid 300-600 mg daily + selenium 100-200 mcg daily + vitamin C 500-1000 mg daily + vitamin E 200-400 IU daily. For mitochondrial support, add Methylene Blue 15-30 mg daily and NAD+ precursor 500-1000 mg daily. For liver-specific support, add milk thistle 300 mg daily and TUDCA 500 mg daily. For peptide stacks: GSH pairs cleanly with BPC-157, TB-500, GHK-Cu, and most other research peptides without known interactions. The practical advice: pick a stack aligned with your specific goal (liver, mitochondrial, longevity, skin), introduce components one at a time over 2-4 weeks each, and monitor relevant biomarkers. A shotgun approach of 15 supplements at once makes attribution impossible.
Research Tools
Related Compounds
View AllARA-290
RecoveryPreclinicalARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.
BPC-157/TB-500 Blend
RecoveryPreclinicalCombined healing peptide blend.
Bronchogen
RecoveryPreclinicalBronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
CAG
RecoveryPreclinicalCAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications.
Cardiogen
RecoveryPreclinicalCardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.
Cartalax
RecoveryPreclinicalCartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.
Side-by-Side Comparisons
All ComparisonsCompare Glutathione head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.